GWM
ADMA icon

Gilpin Wealth Management’s ADMA Biologics ADMA Stock Holding History

Gilpin Wealth Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$452 Buy
45
+20
+80% +$185 ﹤0.01% 873
2026
Q2 		$210 Hold
25
– – ﹤0.01% 904
2026
Q1 		$226 Buy
25
+5
+25% +$79 ﹤0.01% 831
2025
Q4 		$365 Buy
+20
New +$337 ﹤0.01% 501

Other funds holding ADMA

CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $880M AUM 10.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Gilpin Wealth Management's ADMA Position: Q3 2026 in Review

Gilpin Wealth Management increased its ADMA Biologics (ADMA) stake by 80% in Q3 2026, buying an estimated $185 and bringing the position to 45 shares worth $452. The position accounts for ﹤0.01% of the portfolio, ranked #873.

Gilpin Wealth Management first reported a position in ADMA in Q4 2025 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Gilpin Wealth Management held 45 shares of ADMA Biologics worth $452 as of Q3 2026.
  • Gilpin Wealth Management bought 20 ADMA Biologics shares in Q3 2026, an estimated $185.
  • ADMA Biologics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #873 holding.
  • Gilpin Wealth Management first reported a position in ADMA Biologics in Q4 2025 and has held it in 4 quarters since.
  • 10 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.